168 related articles for article (PubMed ID: 35176809)
1. Venetoclax for arsenic-resistant acute promyelocytic leukaemia.
Wang QQ; Wang HF; Zhao JZ; Naranmandura H; Jin J; Zhu HH
Br J Haematol; 2022 Jun; 197(5):e58-e60. PubMed ID: 35176809
[No Abstract] [Full Text] [Related]
2. Venetoclax overcomes resistance to all-trans retinoic acid in a variant acute promyelocytic leukemia with TNRC18::RARA fusion.
Xu J; Li H; Wang Z; Wang M; Li Q; Hang X; Xu J; Ji J; Chen C; Liu Y; Niu T
Mol Carcinog; 2024 Apr; 63(4):553-557. PubMed ID: 38131515
[TBL] [Abstract][Full Text] [Related]
3. Variant acute promyelocytic leukaemia with novel NAB2::RARA fusion shows clinical all-trans retinoic acid and arsenic trioxide sensitivity.
Ng Liet Hing M; Ryland GL; Nguyen T; Tiong IS; Dun K; Ninkovic S; Nedumannil R; Westerman DA; Blombery PA; Chan KL; Bajel A
Br J Haematol; 2023 Aug; 202(4):893-896. PubMed ID: 37280781
[No Abstract] [Full Text] [Related]
4. Relapsed/refractory acute promyelocytic leukemia with RARA-LBD region mutation was salvaged by venetoclax: A case report.
Li Y; Yu J; Xu Q; Zhang K
Medicine (Baltimore); 2021 Dec; 100(48):e28076. PubMed ID: 35049232
[TBL] [Abstract][Full Text] [Related]
5. Arsenic trioxide and all-trans retinoic acid in the treatment of children with newly diagnosed acute promyelocytic leukemia.
Li SY; Lu Y; Liu HC; Gang EJ; Le J; Qian SY; Tang SH; Si T; Pei RZ
Leuk Lymphoma; 2021 May; 62(5):1267-1270. PubMed ID: 33439058
[No Abstract] [Full Text] [Related]
6. Fertility and parenthood in patients with acute promyelocytic leukemia treated with Arsenic Trioxide and All-Trans retinoic acid.
Singh C; Saini M; Jain A; Lad D; Prakash G; Khadwal A; Naseem S; Malhotra P
Blood Cancer J; 2024 Jan; 14(1):14. PubMed ID: 38238308
[No Abstract] [Full Text] [Related]
7. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.
Iland HJ; Collins M; Bradstock K; Supple SG; Catalano A; Hertzberg M; Browett P; Grigg A; Firkin F; Campbell LJ; Hugman A; Reynolds J; Di Iulio J; Tiley C; Taylor K; Filshie R; Seldon M; Taper J; Szer J; Moore J; Bashford J; Seymour JF;
Lancet Haematol; 2015 Sep; 2(9):e357-66. PubMed ID: 26685769
[TBL] [Abstract][Full Text] [Related]
8. Higher than normal mitochondrial DNA content associated with better outcome in acute promyelocytic leukaemia? Maybe.
Wiernik PH
Br J Haematol; 2023 Jan; 200(2):126-127. PubMed ID: 36342482
[TBL] [Abstract][Full Text] [Related]
9. Severe Wernicke encephalopathy and acute pancreatitis due to all-trans-retinoic acid and arsenic trioxide during treatment of acute promyelocytic leukaemia: a case report.
Jiang Y; Ji L
J Int Med Res; 2020 Sep; 48(9):300060520959487. PubMed ID: 32993392
[TBL] [Abstract][Full Text] [Related]
10. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
[TBL] [Abstract][Full Text] [Related]
11. Differentiation therapy using low-dose venetoclax in a variant acute promyelocytic leukaemia carrying ZBTB16-RARA.
Li H; Xiang X; Ding H; Yu J; Xu J; Yuan Y; Wu Y
Br J Haematol; 2022 Dec; 199(5):768-771. PubMed ID: 36169236
[No Abstract] [Full Text] [Related]
12. [Arsenic trioxide, a new drug for the treatment of acute promyelocytic leukemia resistant to tretinoine].
Haanen C; Vermes I
Ned Tijdschr Geneeskd; 1999 Aug; 143(34):1738-41. PubMed ID: 10494320
[TBL] [Abstract][Full Text] [Related]
13. Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide.
Au WY; Chim CS; Lie AK; Liang R; Kwong YL
Br J Haematol; 2002 Apr; 117(1):130-2. PubMed ID: 11918543
[TBL] [Abstract][Full Text] [Related]
14. Addition of Arsenic Trioxide into Induction Regimens Could Not Accelerate Recovery of Abnormality of Coagulation and Fibrinolysis in Patients with Acute Promyelocytic Leukemia.
Zhang Y; Wu S; Luo D; Zhou J; Li D
PLoS One; 2016; 11(1):e0147545. PubMed ID: 26812490
[TBL] [Abstract][Full Text] [Related]
15. Molecular remission without blood product support using all-trans retinoic acid (ATRA) induction and combined arsenic trioxide/ATRA consolidation in a Jehovah's Witness with de novo acute promyelocytic leukaemia.
Kennedy GA; Marlton P; Cobcroft R; Gill D
Br J Haematol; 2000 Dec; 111(4):1103-5. PubMed ID: 11167746
[TBL] [Abstract][Full Text] [Related]
16. Retinoic acid syndrome induced by arsenic trioxide in treating recurrent all-trans retinoic acid resistant acute promyelocytic leukemia.
Che-Pin Lin ; Huang MJ; Chang IY; Lin WY; Sheu YT
Leuk Lymphoma; 2000 Jun; 38(1-2):195-8. PubMed ID: 10811463
[TBL] [Abstract][Full Text] [Related]
17. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.
Zhu HH; Wu DP; Du X; Zhang X; Liu L; Ma J; Shao ZH; Ren HY; Hu JD; Xu KL; Wang JW; Song YP; Fang MY; Li J; Yan XY; Huang XJ
Lancet Oncol; 2018 Jul; 19(7):871-879. PubMed ID: 29884593
[TBL] [Abstract][Full Text] [Related]
18. A Case of Relapsed/Refractory CD56-Positive Acute Promyelocytic Leukemia, in Which Complete Molecular Remission Was Achieved Following Combination Therapy with Venetoclax and Azacitidine.
Sekiguchi Y; Tsutsumi H; Gomyo A; Kudo M; Maseki N; Iizaki Y; Kawamura M; Kobayashi K; Nitta H; Noguchi M; Wakita S; Yamaguchi H; Kobayashi H
Gan To Kagaku Ryoho; 2024 Mar; 51(3):291-297. PubMed ID: 38494811
[TBL] [Abstract][Full Text] [Related]
19. Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
Kantarjian HM; Kadia TM; DiNardo CD; Welch MA; Ravandi F
Cancer; 2021 Apr; 127(8):1186-1207. PubMed ID: 33734442
[TBL] [Abstract][Full Text] [Related]
20. A novel HNRNPC-RARA fusion in acute promyelocytic leukaemia lacking PML-RARA rearrangement, sensitive to venetoclax-based therapy.
Liu M; Zhao X; Pan W; Qian Z; Du M; Wang LM; Huang H; Xiao H
Br J Haematol; 2021 Oct; 195(2):e123-e128. PubMed ID: 34254314
[No Abstract] [Full Text] [Related]
[Next] [New Search]
